UBS Group’s Clinuvel Pharmaceuticals CUVL Stock Holding History

UBS Group’s Portfolio CUVL Stock Details CUVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$181K	Buy	+30,325	New	+$197K	﹤0.01%	6819

Other funds holding CUVL

Shade Tree Advisors Saratoga Springs, New York $187M AUM 53.88% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

UBS Group's CUVL Position: Q3 2026 in Review

UBS Group opened a new position in Clinuvel Pharmaceuticals (CUVL) in Q3 2026: 30,325 shares worth $181K. The stake represents ﹤0.01% of the portfolio and ranks #6819 among its holdings.

6 funds tracked by Wall St. Rank hold CUVL as of Q3 2026.

UBS Group held 30,325 shares of Clinuvel Pharmaceuticals worth $181K as of Q3 2026.
Clinuvel Pharmaceuticals was a new UBS Group position in Q3 2026.
Clinuvel Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6819 holding.
6 funds tracked by Wall St. Rank held Clinuvel Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.